Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


19 abril 2013

Cook Medical introduces new fully-retractable embolization coil

Interventional News

Cook Medical has launched a new fully-retractable .035 inch embolization coil, intended for peripheral arterial and venous embolization. Cook showcased the Retracta Detachable Embolization Coil at the annual Society of Interventional Radiology (SIR) meeting (New Orleans, USA).

16 abril 2013

Global clinical study initiated to determine safety and effectiveness of stent for patients with iliofemoral venous obstruction

Vascular News

Cook Medical has launched the VIVO clinical research study to evaluate the safety and effectiveness of the Zilver Vena Venous Self-Expanding Stent in the treatment of symptomatic iliofemoral venous outflow obstruction. This disease is characterised by leg pain, throbbing, swelling and skin discoloration in the legs. The Zilver Vena venous stent was designed specifically for the dynamic environment of the iliofemoral veins.

10 abril 2013

Colegio médico de EEUU cuestiona la pesquisa del cáncer prostático

Reuters Health

El Colegio Estadounidense de Médicos Internistas (ACP, por su sigla en inglés) acaba de pedirles a los médicos que analicen los beneficios limitados y los "riesgos significativos" de la pesquisa del cáncer prostático antes de ofrecerles a sus pacientes el análisis del antígeno prostático específico (PSA). La declaración, publicada en Annals of Internal Medicine, también desaconseja la pesquisa antes de los 50 años, en los mayores de 69 o en los pacientes con menos de 10 ó 15 años de expectativa de vida.

09 abril 2013

Después de un ACV isquémico es común el dolor crónico

Reuters Health

Un estudio revela que una de cada 10 personas que padecen un accidente cerebrovascular (ACV) isquémico desarrolla dolor crónico. Los autores hallaron que el 10 por ciento de unos 16.000 participantes comenzaron con dolor crónico después del ACV. Eso estuvo asociado con un aumento del riesgo de padecer deterioro físico y mental.

09 abril 2013

Renal denervation should not be part of routine clinical practice, delegates say

Vascular News

At today’s CX Renal Denervation Session Great Debate, delegates voted 3:1 against the motion that renal denervation should be used routinely to treat hypertension. As all of the speakers, regardless of which side of the debate they were, agreed that renal denervation should only be used to treat patients with resistant hypertension, the real focus of the debate centred on what was meant by the word “routine”.

09 abril 2013

CT is the best imaging modality for deep vein thrombosis

Vascular News

Gerard O Sullivan, Galway, Ireland, spoke in the Venous Challenges sessions on Tuesday 9 April about imaging for iliac deep vein thrombosis and the best modalities to use. He told delegates that computed tomography pulmonary angiography (CTPA) and CT venography are his preferred modalities.

13 marzo 2013

Knowing the long-term benefits of renal denervation is a priority

Interventional News. By Jan Staessen

Hypertension affects an estimated 20% to 30% of the world’s adult population. Despite the availability of numerous safe and effective pharmacological therapies, including single pill combinations of two to three drugs, the percentage of patients achieving adequate blood pressure control meeting guideline targets remains low.

04 marzo 2013

Myths about interventional management of vascular malformations: general approach and diagnosis

Interventional News. By Ahmad Alomari

Vascular anomalies can be broadly classified into vascular tumours (eg. infantile haemangioma) and vascular malformations. The two main categories of vascular malformations are slow-flow (venous, lymphatic and capillary malformations) or fast-flow (arteriovenous malformations and fistulas). The interventional management of vascular malformations is the primary minimally-invasive therapy which largely replaced the surgical approach. The use of accurate terminology to describe this heterogenous, occasionally overlapping group of disorders is crucial for proper management and research. Unfortunately, despite the major improvement in the clinical, genetic and therapeutic management of vascular anomalies, myths and misconceptions about the diagnosis and management of these anomalies continue to be surprisingly pervasive with frequent serious consequences.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.